DOI QR코드

DOI QR Code

Feasibility Study of Docetaxel and Cyclophosphamide Six- Cycle Therapy as Adjuvant Chemotherapy for Japanese Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients

  • Abe, Hajime (Breast Center, Bell Land General Hospital) ;
  • Mori, Tsuyoshi (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Kawai, Yuki (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Tomida, Kaori (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Kubota, Yoshihiro (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Umeda, Tomoko (Division of Breast and General Surgery, Shiga University of Medical Science) ;
  • Tani, Tohru (Department of Surgery, Shiga University of Medical Science)
  • Published : 2013.08.30

Abstract

Background: We compared treatment completion rates and safety of docetaxel and cyclophosphamide sixcycle therapy (TC6) with docetaxel followed by 5FU, epirubicin and cyclophosphamide (T-FEC) therapy in Japanese patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Materials and Methods: We administered TC6 q3w or T-FEC q3w to HER2-negative breast cancer patients. The primary endpoint of this trial was toxicity. As second endpoints, the treatment completion rate and relative dose intensity were evaluated. Results: The TC6 and T-FEC group consisted of 22 and 21 patients, respectively. Concerning hematological toxicity, grade 3 or higher adverse reactions included neutropenia and febrile neutropenia. As non-hematological adverse events, exanthema and peripheral neuropathy were frequently reported in the TC6 group, whereas more patients of the T-FEC group reported nausea and vomiting. In TC6, the treatment completion rate was 86.4% and the relative dose intensity of docetaxel was 93.2%. In T-FEC, the values were 95.2% and 98.9%, respectively. Conclusions: These results suggest that TC6 is tolerable in Japanese, and that this regimen can also be performed in outpatient clinics. However, with the TC6 regimen, the compliance was slightly lower than with the T-FEC regimen, and supportive therapy needs to be managed appropriately.

Keywords

Early breast cancer;adjuvant chemotherapy;cyclophosphamide;docetaxel;feasibility

References

  1. De Laurentiis M, Cancello G, D’Agostino D, et al (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 26, 44-53. https://doi.org/10.1200/JCO.2007.11.3787
  2. Eiermann W, Pienkowski T, Crown J, et al (2011). Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2.normal, node-positive breast cancer: BCIRG-005 Trial. J Clin Oncol, 29, 3877-84. https://doi.org/10.1200/JCO.2010.28.5437
  3. Fisher B, Jeong JH, Anderson S, et al (2004). Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst, 96, 1823-31. https://doi.org/10.1093/jnci/djh338
  4. Fumoleau P, Roche´ H, Kerbrat P, et al (2006). French adjuvant study group: long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol, 17, 85-92. https://doi.org/10.1093/annonc/mdl243
  5. Abe H, Mori T, Kawai Y, et al (2012). Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. Int J Clin Oncol, 18, 487-91.
  6. Bonadonna G, Moliterni A, Zambetti M, et al (2005). 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ, 330, 217. https://doi.org/10.1136/bmj.38314.622095.8F
  7. Ganz PA, Land SR, Geyer CE Jr, et al (2011). Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol, 29, 1110-6. https://doi.org/10.1200/JCO.2010.29.7689
  8. Iwata H, Sato N, Masuda N, et al (2011). Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol, 41, 867-75. https://doi.org/10.1093/jjco/hyr081
  9. Jones SE, Savin MA, Holmes FA, et al (2006). Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol, 24, 5381-7. https://doi.org/10.1200/JCO.2006.06.5391
  10. Jones S, Holmes FA, O’Shaughnessy J, et al (2009). Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol, 27, 1177-83. https://doi.org/10.1200/JCO.2008.18.4028
  11. Martin M, Pienkowski T, Mackey J, et al (2005). Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med, 352, 2302-13. https://doi.org/10.1056/NEJMoa043681
  12. Roche H, Fumoleau P, Spielmann M, et al (2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol, 24, 5664-71. https://doi.org/10.1200/JCO.2006.07.3916
  13. Takabatake D, Taira N, Hara F, et al (2009). Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for japanese breast cancer patients. Jpn J Clin Oncol, 39, 478-83. https://doi.org/10.1093/jjco/hyp050

Cited by

  1. Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951